argenx to Present at 44th Annual J.P. Morgan Healthcare Conference January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx...
argenx announced that Karen Massey, current COO, will transition to CEO and executive director and Tim Van Hauwermeiren, current CEO, will transition to non-executive director and chairman of the board. We believe Karen is a strong fit for the CEO role as an internal candidate who, in her capacity as COO, helped shape the company's Vision 2030 and built its commercial engine. Based on our conversation with management, Karen will focus on ensuring continuity and executing argenx' strategy, while...
argenx Announces Leadership Transition Marking Next Evolution of Growth Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director an...
DEME secures two marine works contracts in Italy and Spain DEME’s Dredging & Infra segment has secured two marine works contracts in Southern Europe, highlighting its expertise in environmental remediation and coastal protection. In Italy, DEME will deliver marine works for the prestigious 38th America’s Cup sailing competition in Naples, including offshore breakwaters and seabed remediation at the Bagnoli-Coroglio site. Meanwhile, in Spain, DEME will restore three beaches along the Valencian coastline through a large-scale nourishment project, to combat erosion and safeguard the shoreline ...
DEME haalt twee contracten binnen voor maritieme werken in Italië en Spanje DEME’s Dredging & Infra-segment heeft twee contracten voor maritieme werken binnengehaald in Zuid-Europa, die de expertise op het gebied van milieusanering en kustbescherming in de verf zetten. In Italië zal DEME maritieme werken uitvoeren voor de prestigieuze 38ste America’s Cup-zeilwedstrijd in Napels, waaronder golfbrekers en sanering van de zeebodem op de site Bagnoli-Coroglio. In Spanje zal DEME drie stranden langs de Valenciaanse kustlijn herstellen via een grootschalig ophogingsproject, om erosie tegen te gaa...
DEME wins contract to help restore water quality in the central Netherlands DEME has won a contract to implement WFD (Water Framework Directive) measures in Central Netherlands. WFD measures are projects aimed at improving water quality in the Netherlands, which are carried out by Rijkswaterstaat. In collaboration with its partner Beens Dredging B.V. (part of Beens Groep B.V.), DEME will execute Lot D at the locations Eemmeer, Ketelmeer, and Zwarte Meer. These works will start in April 2026 and are expected to be completed by December 2027. Attachment ...
DEME wint contract voor herstel van waterkwaliteit in Midden-Nederland DEME heeft een contract getekend voor de uitvoering van KRW-maatregelen in Midden-Nederland. KRW-maatregelen (Kaderrichtlijn Water) zijn projecten die gericht zijn op het verbeteren van de waterkwaliteit in Nederland, uitgevoerd door Rijkswaterstaat. In samenwerking met partner Beens Dredging B.V. (onderdeel van Beens Groep B.V.) zal DEME Perceel D uitvoeren op de locaties Eemmeer, Ketelmeer en Zwarte Meer. De werkzaamheden starten in april 2026 en de voltooiing wordt verwacht in december 2027. Bijlage ...
argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...
DEME secures foundation and cable installation contracts for BC-Wind offshore wind farm in Poland DEME has been awarded three contracts for the installation of monopile foundations, inter-array cables, and the export cable at the BC-Wind offshore wind farm in Poland. These new contracts position DEME as a key contributor to Poland’s renewable energy build-out, supporting the country’s energy transition. Attachment
DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind offshore windpark in Polen DEME heeft drie contracten gewonnen voor de installatie van monopile funderingen, inter-arraykabels en de exportkabel voor het BC-Wind offshore windpark in Polen. Deze nieuwe contracten positioneren DEME als een belangrijke speler in de uitbouw van hernieuwbare energie in Polen en ondersteunen de energietransitie van het land. Bijlage
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.